Viatris Inc (VTRS : NASDAQ)
Common Stock
$17.25
USD
-0.29 (-1.65%)
Last updated: 2026-10-13
Follow VTRS
VTRS
Viatris Inc
WealthAwesomePerformance
1 Day
-1.65%
1 Week
-1.65%
1 Month
+4.48%
YTD
+41.71%
Key Statistics
Market Cap
$20.15B
52W High
$18.43
52W Low
$9.58
P/E Ratio
-
50 Day MA
$16.93
200 Day MA
$15.49
Beta
0.86
Dividend Yield
2.72%
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/13/2026 | $17.66 | $17.66 | $17.20 | $17.25 | $17.25 | 7,547,542 |
| 10/12/2026 | $17.70 | $17.79 | $17.53 | $17.54 | $17.54 | 7,550,600 |
| 10/9/2026 | $17.36 | $17.76 | $17.19 | $17.64 | $17.64 | 8,831,100 |
| 10/8/2026 | $17.26 | $17.52 | $16.89 | $17.44 | $17.44 | 14,109,977 |
| 10/7/2026 | $17.52 | $17.82 | $17.41 | $17.49 | $17.49 | 7,543,511 |
| 10/6/2026 | $17.77 | $17.87 | $17.31 | $17.54 | $17.54 | 6,675,700 |
| 10/5/2026 | $17.82 | $17.90 | $17.45 | $17.62 | $17.62 | 6,356,515 |
| 10/2/2026 | $17.53 | $17.65 | $17.34 | $17.60 | $17.60 | 7,525,600 |
| 10/1/2026 | $17.62 | $17.84 | $17.43 | $17.46 | $17.46 | 9,038,600 |
| 9/30/2026 | $18.16 | $18.17 | $17.71 | $17.72 | $17.72 | 11,806,700 |
Analyst Price Targets
Based on 12 analysts covering VTRS · as of Oct 7, 2026
Wall Street analysts forecast VTRS stock price to rise 14.2% over the next 12 months.
Consensus
Buy4.00 / 5.00
Avg. Target
US$19.70
+14.2% Upside
Previously US$19.40 on Oct 5, 2026
Current Price
US$17.25
Last close
Analyst Breakdown (12 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on VTRS's historical volatility
30-Day Vol
20.5%
Annualized
90-Day Vol
27.7%
Annualized
Trend (90d)
+9.5%
Annualized drift
90d Mean
US$17.85
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$17.45 | US$16.26 – US$18.73 |
| 60 trading days | US$17.65 | US$15.97 – US$19.50 |
| 90 trading days | US$17.85 | US$15.79 – US$20.17 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Viatris Inc
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Financials
- Revenue (TTM)
- $14.74B
- EBITDA
- $4.29B
- Profit Margin
- -2.79%
- ROE (TTM)
- -2.75%
- EPS (Diluted)
- -0.36
- Book Value
- 12.59
Classification
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About VTRS.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| JBDI | JBDI Holdings Limited Ordinary Shares | $3.43 | +251.79% |
| TCRT | Alaunos Therapeutics Inc | $3.03 | +188.57% |
| PFAI | Pinnacle Food Group Limited Class A Common Shares | $4.70 | +80.08% |
| KFIIR | K&F Growth Acquisition Corp. II Rights | $0.10 | +74.71% |
| FLYE | Fly-E Group, Inc. Common Stock | $3.55 | +73.17% |
| BKYI | BIO-key International, Inc. Common Stock | $2.83 | +71.52% |
| JYD | Jayud Global Logistics Limited Class A Ordinary Shares | $1.46 | +56.97% |
| FEED | ENvue Medical Inc. | $0.55 | +56.61% |
VTRS.US news timeline
1 article covering VTRS.US, most recent first
Latest